This page shows the latest Cellectis news and features for those working in and with pharma, biotech and healthcare.
The deal with Sangamo means rivals in the CAR-T category such asand off-the-shelf specialist Cellectis won’t be able to use the ZFN technology in their own ... Other techniques include CRISPR/Cas9 - used by Novartis and Juno - and Cellectis’favoured
Cellectis floored by patient death in CAR-T trial. FDA puts two cancer immunotherapy trials on hold. ... It may be that the FDA will exercise greater caution in Cellectis' case.
The French pharma company entered the race to develop chimeric antigen receptor therapies (CAR-T) for cancer after it acquired exclusive rights to UCART19 from Cellectis in 2015. ... Cellectis specialises in the development of ‘off-the-shelf’CAR-T
Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial. Investigational New Drug gets go-ahead for trials in patients with two haematological cancers. ... This is not the first time that one of Cellectis' CAR-T candidates has been tested in patients
The green light is a relief to Juno but could raise a warning flag for other companies developing CAR-T therapies, which includeand Cellectis, among others.
Other recent deals include Pfizer and Servier's collaboration with Cellectis - signed last November - as well as Merck &Co's $941m alliance with Intrexon, Amgen's $1bn collaboration with Kite Pharma
More from news
Approximately 8 fully matching, plus 9 partially matching documents found.
379. Cellectis. Servier. Option exercise. UCART19, CAR-T allogeneic immunotherapy being tested for chronic lymphocytic leukaemia and acute lymphoblastic leukaemia.
Following the collaboration announced in June 2014 with Cellectis, the rumours are now going around that Pfizer may be planning an acquisition with an estimated price tag of $1.6bn.
Also Evaluate reports a cautious approach by big pharma. Novartis, J&J and Pfizer (via a deal with Cellectis) are in the go-kart race but other companies such as Merck
Cellectis has reserved 12 other targets and Pfizer will provide preclinical development assistance for four of these. ... easily. Cellectis plans to open a research site in the US to work more closely with Pfizer.
350. Medreich/ Meiji Seika. Company acquisition. India-based manufacturing company. 290. Cellectis/ Pfizer.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Arjan Roozen, who previously headed up the GMP solutions and manufacturing team at French cell therapy group Cellectis, comes with expertise in microbiology and molecular microbiology.
Cellectis’ Mathieu Simon will serve as interim chief medical officer. He will take over the responsibilities of Loan Hoang-Sayag. ... Cellectis has appointed Mathieu Simon to as interim chief medical officer, taking over the role from Loan Hoan-Sayag,
I see exciting opportunities for Cellectis to address unmet medical needs and make a meaningful difference in people’s lives. ... I am excited to be joining the Cellectis board during this important time of growth.”.
Meanwhile, Pierre Schwich (pictured left) joins Pharnext from Cellectis where he served as chief financial officer from 2011 until 2014. ... Before joining Cellectis, he served as chief financial officer and corporate secretary for Genesys Conferencing,
More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.
Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....